- Home
- XERS vs AAT Comparison
XERS vs AAT Comparison
Compare XERS & AAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XERS | AAT |
|---|---|---|
| Founded | 2005 | 1967 |
| Country | United States | United States |
| Employees | N/A | 208 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2021 | 2010 |
Fundamental Metrics
Financial Performance| Metric | XERS | AAT |
|---|---|---|
| Price | $8.85 | $22.60 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 6 | 2 |
| Target Price | $10.83 | ★ $19.50 |
| AVG Volume (30 Days) | ★ 1.6M | 380.1K |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 6.65% |
| EPS Growth | ★ 100.00 | N/A |
| EPS | N/A | ★ 0.08 |
| Revenue | $49,590,000.00 | ★ $436,204,000.00 |
| Revenue This Year | $34.37 | $4.33 |
| Revenue Next Year | $22.86 | $0.22 |
| P/E Ratio | ★ N/A | $283.13 |
| Revenue Growth | ★ 142.67 | N/A |
| 52 Week Low | $5.25 | $17.72 |
| 52 Week High | $10.08 | $25.97 |
Technical Indicators
Market Signals| Indicator | XERS | AAT |
|---|---|---|
| Relative Strength Index (RSI) | 59.95 | 38.54 |
| Support Level | $6.98 | $17.92 |
| Resistance Level | $9.01 | $25.76 |
| Average True Range (ATR) | 0.35 | 0.47 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 94.66 | 24.97 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About AAT American Assets Trust Inc.
American Assets Trust Inc is a self-administered real estate investment trust based in the United States. The company invests in, operates, and develops retail, office, residential, and mixed-use properties. Properties are predominantly located in South California, Northern California, Oregon, Washington, and Hawaii. American Assets operates through four segments based on property type: retail; office; mixed-use, which consists of retail and hotel components; and multifamily, which includes the company's apartment properties. The retail and office segments collectively contribute the majority of the total revenue.